Archives
A Milk-Locus Strategy for Rabbit Protein Pharming
2026-11-11
A proof-of-concept study tested whether placing a reporter gene at the rabbit CSN2 locus could support abundant milk expression and stable inheritance. The findings support the biological rationale, while remaining limited to a reporter protein and a small animal set.
What High-Yield Rabbit Pharming Evidence Shows
2026-11-10
A targeted rabbit line produced 15–20 g/L of a recombinant reporter protein in milk, but the result is best interpreted as a proof of concept for locus-directed expression rather than as a general production benchmark.
Why CSN2 Targeting Raises Rabbit Milk Output
2026-11-10
A mechanistic reading of evidence linking endogenous CSN2-locus targeting with high recombinant-protein concentrations in rabbit milk, including what the study establishes, what remains confounded, and how broadly the result can be applied.
What a CSN2 Rabbit Pharming Study Shows
2026-11-09
A 2025 study examined whether targeted placement of a reporter gene under the rabbit CSN2 milk-protein regulatory region could raise recombinant protein output. Its results are striking but preliminary: high milk concentrations were reported in two homozygous animals, while broader questions about cargo-specific performance, product quality, animal physiology and reproducibility remain open.
Why CSN2 Targeting Matters in Rabbit Pharming
2026-11-09
A literature-focused analysis of a 2025 study showing that targeted placement of a reporter transgene under the rabbit CSN2 regulatory context was associated with markedly higher milk concentrations than conventional pharming benchmarks, while emphasizing the study’s small animal number, reporter-based readout, and limits on therapeutic generalization.
A Targeted Route to Higher Rabbit Pharming Yields
2026-11-08
Song and colleagues tested whether placing a reporter gene under the endogenous rabbit CSN2 milk-protein promoter could overcome the variability and low output associated with conventional transgenic pharming. The study reported 15–20 g/L tdTomato in milk from two homozygous rabbits, while also highlighting important limits: the result concerns a reporter protein, a small animal group, and cross-study comparisons rather than a direct therapeutic-protein manufacturing trial.
Why the CSN2 Locus Raises Rabbit Pharming Yield
2026-11-07
A targeted insertion strategy placed a reporter gene under the endogenous rabbit CSN2 regulatory context, producing substantially higher milk concentrations than most historically reported rabbit pharming lines. The result supports a strong locus-dependent effect, but remains a proof of concept because the main quantitative result came from a reporter protein and a small number of homozygous animals.
When Context Changes a Pharming Result
2026-11-06
A high concentration in rabbit milk can demonstrate successful expression without, by itself, proving therapeutic-product performance or industrial productivity. The meaning of the result depends on the genetic locus, reporter, comparator, animal cohort and measurement used.
Reciprocal Glial Signaling in Spinal Cord Repair
2026-11-06
A mouse study supports a reciprocal repair model in which astrocyte-derived CSF1 supports lesion-associated microglia, while microglial IFN-β signaling supports astrocyte survival and coordinated wound repair. Genetic perturbations and rescue experiments indicate that the two pathways cooperate but are not interchangeable.
What a High-Yield Rabbit Pharming Study Shows
2026-11-05
A recent rabbit study links targeted integration at the endogenous CSN2 milk-protein locus with markedly higher reporter-protein concentrations than those commonly reported for conventional transgenic lines. The result is biologically plausible and quantitatively notable, but it remains a proof-of-concept rather than a definitive head-to-head demonstration. The small number of high-producing animals, use of tdTomato rather than a therapeutic protein, historical rather than matched comparators, and unresolved questions about product quality and long-term consistency all limit how broadly the finding can be generalized.
Why CSN2 Matters for Rabbit Pharming
2026-11-05
A literature-focused analysis of how targeted expression from the endogenous CSN2 locus was associated with markedly higher recombinant protein levels in rabbit milk, while distinguishing reporter expression from therapeutic-product validation.
CSN2 Targeting and Rabbit Pharming Yield
2026-11-04
A 2025 study links targeted insertion at the endogenous CSN2 milk-protein locus with unusually high tdTomato concentrations in rabbit milk. The findings support a mechanistic role for promoter context and controlled genomic placement, but the small reporter-focused dataset does not yet establish equivalent performance for therapeutic proteins or prove that promoter choice alone caused the increase.
Why CSN2 Targeting Raised Rabbit Pharming Yields
2026-11-04
A literature-focused analysis of how targeted insertion at the rabbit CSN2 locus was linked to high reporter-protein concentrations in milk, what the study actually demonstrated, and which uncertainties limit interpretation beyond this reporter model.
Targeted Rabbit Pharming: What the Evidence Shows
2026-11-03
A 2025 study linked targeted insertion at the rabbit CSN2 locus with substantially higher reporter-protein levels in milk, but the result remains an early, small-scale demonstration rather than proof of general therapeutic-protein manufacturing performance.
The CSN2 Locus and High-Yield Rabbit Pharming
2026-11-03
A targeted rabbit line links an endogenous milk-protein regulatory locus to markedly higher reporter concentration in milk, but the evidence supports feasibility rather than a universal production rule. The key mechanistic uncertainty is how much of the result comes from promoter context, targeted integration, allele dosage, or properties specific to the reporter protein.